337 related articles for article (PubMed ID: 23372805)
1. The prognostic value of epigenetic silencing of p16 gene in NSCLC patients: a systematic review and meta-analysis.
Lou-Qian Z; Rong Y; Ming L; Xin Y; Feng J; Lin X
PLoS One; 2013; 8(1):e54970. PubMed ID: 23372805
[TBL] [Abstract][Full Text] [Related]
2. The Prognostic Value of p16 Hypermethylation in Cancer: A Meta-Analysis.
Xing XB; Cai WB; Luo L; Liu LS; Shi HJ; Chen MH
PLoS One; 2013; 8(6):e66587. PubMed ID: 23805242
[TBL] [Abstract][Full Text] [Related]
3. Differential impact of p16 inactivation by promoter methylation in non-small cell lung and colorectal cancer: clinical implications.
González-Quevedo R; García-Aranda C; Morán A; De Juan C; Sánchez-Pernaute A; Torres A; Díaz-Rubio E; Balibrea JL; Benito M; Iniesta P
Int J Oncol; 2004 Feb; 24(2):349-55. PubMed ID: 14719111
[TBL] [Abstract][Full Text] [Related]
4. Promoter hypermethylation of the p16 and Wif-1 genes as an independent prognostic marker in stage IA non-small cell lung cancers.
Yoshino M; Suzuki M; Tian L; Moriya Y; Hoshino H; Okamoto T; Yoshida S; Shibuya K; Yoshino I
Int J Oncol; 2009 Nov; 35(5):1201-9. PubMed ID: 19787276
[TBL] [Abstract][Full Text] [Related]
5. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
6. Expression of p16 in non-small cell lung cancer and its prognostic significance: a meta-analysis of published literatures.
Tong J; Sun X; Cheng H; Zhao D; Ma J; Zhen Q; Cao Y; Zhu H; Bai J
Lung Cancer; 2011 Nov; 74(2):155-63. PubMed ID: 21621871
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis.
Wang J; Wang B; Chen X; Bi J
Carcinogenesis; 2011 Mar; 32(3):411-6. PubMed ID: 21156971
[TBL] [Abstract][Full Text] [Related]
8. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients.
Bradly DP; Gattuso P; Pool M; Basu S; Liptay M; Bonomi P; Buckingham L
Diagn Mol Pathol; 2012 Dec; 21(4):207-13. PubMed ID: 23111194
[TBL] [Abstract][Full Text] [Related]
9. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
Kim JS; Kim JW; Han J; Shim YM; Park J; Kim DH
Cancer Res; 2006 Apr; 66(8):4049-54. PubMed ID: 16618724
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of p16(INK4a) hypermethylation in non-small cell lung cancer is evident by quantitative DNA methylation analysis.
Ota N; Kawakami K; Okuda T; Takehara A; Hiranuma C; Oyama K; Ota Y; Oda M; Watanabe G
Anticancer Res; 2006; 26(5B):3729-32. PubMed ID: 17094392
[TBL] [Abstract][Full Text] [Related]
11. Prognostic role of B7-H4 in patients with non-small cell lung cancer: A meta-analysis.
Tan Z; Shen W
Oncotarget; 2017 Apr; 8(16):27137-27144. PubMed ID: 28404927
[TBL] [Abstract][Full Text] [Related]
12. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer.
Bearzatto A; Conte D; Frattini M; Zaffaroni N; Andriani F; Balestra D; Tavecchio L; Daidone MG; Sozzi G
Clin Cancer Res; 2002 Dec; 8(12):3782-7. PubMed ID: 12473590
[TBL] [Abstract][Full Text] [Related]
13. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis.
Meng D; Yuan M; Li X; Chen L; Yang J; Zhao X; Ma W; Xin J
Lung Cancer; 2013 Jul; 81(1):1-10. PubMed ID: 23608713
[TBL] [Abstract][Full Text] [Related]
16. Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer.
Jarmalaite S; Kannio A; Anttila S; Lazutka JR; Husgafvel-Pursiainen K
Int J Cancer; 2003 Oct; 106(6):913-8. PubMed ID: 12918069
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Expression of MicroRNAs in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Zhan B; Lu D; Luo P; Wang B
Clin Lab; 2016 Nov; 62(11):2203-2211. PubMed ID: 28164670
[TBL] [Abstract][Full Text] [Related]
18. [Abnormality of p16 gene and its clinicopathological significance in non-small cell lung cancer].
Fu J; Zhang J; Zhang HW
Zhonghua Bing Li Xue Za Zhi; 2003 Apr; 32(2):133-6. PubMed ID: 12839675
[TBL] [Abstract][Full Text] [Related]
19. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer.
Kim DH; Nelson HH; Wiencke JK; Zheng S; Christiani DC; Wain JC; Mark EJ; Kelsey KT
Cancer Res; 2001 Apr; 61(8):3419-24. PubMed ID: 11309302
[TBL] [Abstract][Full Text] [Related]
20. Cigarette smoking and p16INK4α gene promoter hypermethylation in non-small cell lung carcinoma patients: a meta-analysis.
Zhang B; Zhu W; Yang P; Liu T; Jiang M; He ZN; Zhang SX; Chen WQ; Chen W
PLoS One; 2011; 6(12):e28882. PubMed ID: 22174919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
